Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
- 2011 ISB Systems Biology and P4 Medicine Symposium, Day 1
A summary of talks from day 1 of the Institute for Systems Biology (ISB) 2011 Systems Biology and P4 Medicine symposium.
- 2011 ISB Systems Biology and P4 Medicine Symposium, Day 2
A summary of talks from day 2 of the Institute for Systems Biology (ISB) 2011 Systems Biology and P4 Medicine symposium.
- Alzheimer’s Consortium Identifies Five New Genes for Disease Risk
The Alzheimer’s Disease Genetics Consortium (ADGC) led by the University of Pennsylvania School of Medicine, the University of Miami, and the Boston University School of Medicine, recently identified five new genes linked to late-onset Alzheimer’s disease.
- Triple-Biomarker Approach Improves Chronic Kidney Disease Prediction Accuracy
Researchers have found that a combination biomarker approach improves risk prediction for chronic kidney disease (CKD).
- Thirteen Proteomics Companies Form Proteomics Innovation Network
New England Peptide recently announced that it and twelve other product and service companies have started the global Proteomics Innovation Network to collaborate on unmet needs in drug discovery and personalized medicine.